Apimeds Pharmaceuticals US, Inc.
APUSApimeds Pharmaceuticals US, Inc. is a diversified holding company operating through two distinct business lines: clinical-stage biopharmaceutical development and institutional digital asset treasury solutions.
Table of contents
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Apimeds Pharmaceuticals US, Inc. is a diversified holding company operating through two distinct business lines: clinical-stage biopharmaceutical development and institutional digital asset treasury solutions. The company focuses on developing bee venom-based toxins for inflammatory conditions while simultaneously providing infrastructure for corporations to manage and generate yield on Bitcoin reserves.
The company holds a unique dual-sector position, leveraging licensed clinical data from South Korea for its biotech arm and a Bitcoin-centric reserve strategy for its fintech platform.
Questions, answered.
- What is Apimeds Pharmaceuticals US, Inc.'s market cap?
- Apimeds Pharmaceuticals US, Inc. (APUS) has a market capitalization of $13.6M and trades on AMEX.
- Who are Apimeds Pharmaceuticals US, Inc.'s competitors?
- Apimeds Pharmaceuticals US, Inc.'s key competitors include MicroStrategy Incorporated, Greenlane Holdings, Inc. Class A Common Stock, BNB Plus Corp. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Apimeds Pharmaceuticals US, Inc. partner with?
- Apimeds Pharmaceuticals US, Inc.'s notable partners include Apimeds Inc. (Korea), Piramal Pharma Solutions, Apico, Inc., and others.
- What subsidiaries does Apimeds Pharmaceuticals US, Inc. have?
- Apimeds Pharmaceuticals US, Inc.'s subsidiaries include Lokahi Therapeutics, Inc., MindWave Innovations Inc, TechyTrade Innovations Pte. Ltd., and others.
- Where is Apimeds Pharmaceuticals US, Inc. headquartered?
- Apimeds Pharmaceuticals US, Inc. is headquartered in United States of America and employs approximately 2 people. It has been publicly traded since 2025.